Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758363/
http://dx.doi.org/10.1007/s40278-022-08955-9
_version_ 1784632882876121088
collection PubMed
description
format Online
Article
Text
id pubmed-8758363
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87583632022-01-14 Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports Reactions Weekly Case Report Springer International Publishing 2022-01-15 2022 /pmc/articles/PMC8758363/ http://dx.doi.org/10.1007/s40278-022-08955-9 Text en © Springer International Publishing AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title_full Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title_fullStr Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title_full_unstemmed Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title_short Remdesivir/tocilizumab: Endogenous endophthalmitis: 3 case reports
title_sort remdesivir/tocilizumab: endogenous endophthalmitis: 3 case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758363/
http://dx.doi.org/10.1007/s40278-022-08955-9

Ejemplares similares